nodes	percent_of_prediction	percent_of_DWPC	metapath
Dimenhydrinate—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.0269	0.0269	CcSEcCtD
Dimenhydrinate—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.0198	0.0198	CcSEcCtD
Dimenhydrinate—Neuritis—Vincristine—lymphatic system cancer	0.0177	0.0177	CcSEcCtD
Dimenhydrinate—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.0174	0.0174	CcSEcCtD
Dimenhydrinate—Tinnitus—Mechlorethamine—lymphatic system cancer	0.0156	0.0156	CcSEcCtD
Dimenhydrinate—Wheezing—Bleomycin—lymphatic system cancer	0.0154	0.0154	CcSEcCtD
Dimenhydrinate—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.0135	0.0135	CcSEcCtD
Dimenhydrinate—Sweating increased—Fludarabine—lymphatic system cancer	0.0132	0.0132	CcSEcCtD
Dimenhydrinate—Vertigo—Mechlorethamine—lymphatic system cancer	0.0131	0.0131	CcSEcCtD
Dimenhydrinate—Dysuria—Fludarabine—lymphatic system cancer	0.0127	0.0127	CcSEcCtD
Dimenhydrinate—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.0119	0.0119	CcSEcCtD
Dimenhydrinate—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.0117	0.0117	CcSEcCtD
Dimenhydrinate—Anorexia—Mechlorethamine—lymphatic system cancer	0.0114	0.0114	CcSEcCtD
Dimenhydrinate—Chills—Teniposide—lymphatic system cancer	0.0111	0.0111	CcSEcCtD
Dimenhydrinate—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.0104	0.0104	CcSEcCtD
Dimenhydrinate—Diplopia—Carmustine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Dimenhydrinate—Agitation—Teniposide—lymphatic system cancer	0.0099	0.0099	CcSEcCtD
Dimenhydrinate—Chills—Fludarabine—lymphatic system cancer	0.00976	0.00976	CcSEcCtD
Dimenhydrinate—Urinary retention—Vincristine—lymphatic system cancer	0.00913	0.00913	CcSEcCtD
Dimenhydrinate—Confusional state—Teniposide—lymphatic system cancer	0.00886	0.00886	CcSEcCtD
Dimenhydrinate—Agitation—Fludarabine—lymphatic system cancer	0.0087	0.0087	CcSEcCtD
Dimenhydrinate—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00861	0.00861	CcSEcCtD
Dimenhydrinate—Tachycardia—Teniposide—lymphatic system cancer	0.00858	0.00858	CcSEcCtD
Dimenhydrinate—Hyperhidrosis—Teniposide—lymphatic system cancer	0.0085	0.0085	CcSEcCtD
Dimenhydrinate—Anorexia—Teniposide—lymphatic system cancer	0.00838	0.00838	CcSEcCtD
Dimenhydrinate—Hypotension—Teniposide—lymphatic system cancer	0.00821	0.00821	CcSEcCtD
Dimenhydrinate—Convulsion—Fludarabine—lymphatic system cancer	0.0082	0.0082	CcSEcCtD
Dimenhydrinate—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00816	0.00816	CcSEcCtD
Dimenhydrinate—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00787	0.00787	CcSEcCtD
Dimenhydrinate—Confusional state—Fludarabine—lymphatic system cancer	0.00779	0.00779	CcSEcCtD
Dimenhydrinate—Dysuria—Vincristine—lymphatic system cancer	0.00776	0.00776	CcSEcCtD
Dimenhydrinate—Decreased appetite—Teniposide—lymphatic system cancer	0.00764	0.00764	CcSEcCtD
Dimenhydrinate—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.0076	0.0076	CcSEcCtD
Dimenhydrinate—Vomiting—Mechlorethamine—lymphatic system cancer	0.00758	0.00758	CcSEcCtD
Dimenhydrinate—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00758	0.00758	CcSEcCtD
Dimenhydrinate—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00756	0.00756	CcSEcCtD
Dimenhydrinate—Rash—Mechlorethamine—lymphatic system cancer	0.00752	0.00752	CcSEcCtD
Dimenhydrinate—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00751	0.00751	CcSEcCtD
Dimenhydrinate—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00747	0.00747	CcSEcCtD
Dimenhydrinate—Anorexia—Fludarabine—lymphatic system cancer	0.00736	0.00736	CcSEcCtD
Dimenhydrinate—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00726	0.00726	CcSEcCtD
Dimenhydrinate—Feeling abnormal—Teniposide—lymphatic system cancer	0.00724	0.00724	CcSEcCtD
Dimenhydrinate—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00721	0.00721	CcSEcCtD
Dimenhydrinate—Chills—Bleomycin—lymphatic system cancer	0.00715	0.00715	CcSEcCtD
Dimenhydrinate—Nausea—Mechlorethamine—lymphatic system cancer	0.00708	0.00708	CcSEcCtD
Dimenhydrinate—Urticaria—Teniposide—lymphatic system cancer	0.00698	0.00698	CcSEcCtD
Dimenhydrinate—Paraesthesia—Fludarabine—lymphatic system cancer	0.00694	0.00694	CcSEcCtD
Dimenhydrinate—Dyspepsia—Fludarabine—lymphatic system cancer	0.0068	0.0068	CcSEcCtD
Dimenhydrinate—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00673	0.00673	CcSEcCtD
Dimenhydrinate—Decreased appetite—Fludarabine—lymphatic system cancer	0.00672	0.00672	CcSEcCtD
Dimenhydrinate—Fatigue—Fludarabine—lymphatic system cancer	0.00666	0.00666	CcSEcCtD
Dimenhydrinate—Constipation—Fludarabine—lymphatic system cancer	0.00661	0.00661	CcSEcCtD
Dimenhydrinate—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00637	0.00637	CcSEcCtD
Dimenhydrinate—Asthenia—Teniposide—lymphatic system cancer	0.00631	0.00631	CcSEcCtD
Dimenhydrinate—Diarrhoea—Teniposide—lymphatic system cancer	0.00602	0.00602	CcSEcCtD
Dimenhydrinate—Chills—Mitoxantrone—lymphatic system cancer	0.00581	0.00581	CcSEcCtD
Dimenhydrinate—Confusional state—Bleomycin—lymphatic system cancer	0.00571	0.00571	CcSEcCtD
Dimenhydrinate—Vision blurred—Carmustine—lymphatic system cancer	0.00571	0.00571	CcSEcCtD
Dimenhydrinate—Tremor—Carmustine—lymphatic system cancer	0.00568	0.00568	CcSEcCtD
Dimenhydrinate—Vomiting—Teniposide—lymphatic system cancer	0.00559	0.00559	CcSEcCtD
Dimenhydrinate—Agitation—Carmustine—lymphatic system cancer	0.00557	0.00557	CcSEcCtD
Dimenhydrinate—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Dimenhydrinate—Asthenia—Fludarabine—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Dimenhydrinate—Rash—Teniposide—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Dimenhydrinate—Dermatitis—Teniposide—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Dimenhydrinate—Headache—Teniposide—lymphatic system cancer	0.00551	0.00551	CcSEcCtD
Dimenhydrinate—Anorexia—Bleomycin—lymphatic system cancer	0.0054	0.0054	CcSEcCtD
Dimenhydrinate—Agitation—Vincristine—lymphatic system cancer	0.00532	0.00532	CcSEcCtD
Dimenhydrinate—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00531	0.00531	CcSEcCtD
Dimenhydrinate—Photosensitivity—Methotrexate—lymphatic system cancer	0.00531	0.00531	CcSEcCtD
Dimenhydrinate—Hypotension—Bleomycin—lymphatic system cancer	0.00529	0.00529	CcSEcCtD
Dimenhydrinate—Diarrhoea—Fludarabine—lymphatic system cancer	0.00529	0.00529	CcSEcCtD
Dimenhydrinate—Convulsion—Carmustine—lymphatic system cancer	0.00525	0.00525	CcSEcCtD
Dimenhydrinate—Nausea—Teniposide—lymphatic system cancer	0.00522	0.00522	CcSEcCtD
Dimenhydrinate—Vertigo—Vincristine—lymphatic system cancer	0.0052	0.0052	CcSEcCtD
Dimenhydrinate—Paraesthesia—Bleomycin—lymphatic system cancer	0.00509	0.00509	CcSEcCtD
Dimenhydrinate—Convulsion—Vincristine—lymphatic system cancer	0.00501	0.00501	CcSEcCtD
Dimenhydrinate—Confusional state—Carmustine—lymphatic system cancer	0.00499	0.00499	CcSEcCtD
Dimenhydrinate—Decreased appetite—Bleomycin—lymphatic system cancer	0.00492	0.00492	CcSEcCtD
Dimenhydrinate—Vomiting—Fludarabine—lymphatic system cancer	0.00491	0.00491	CcSEcCtD
Dimenhydrinate—Convulsion—Mitoxantrone—lymphatic system cancer	0.00488	0.00488	CcSEcCtD
Dimenhydrinate—Rash—Fludarabine—lymphatic system cancer	0.00487	0.00487	CcSEcCtD
Dimenhydrinate—Dermatitis—Fludarabine—lymphatic system cancer	0.00487	0.00487	CcSEcCtD
Dimenhydrinate—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00484	0.00484	CcSEcCtD
Dimenhydrinate—Headache—Fludarabine—lymphatic system cancer	0.00484	0.00484	CcSEcCtD
Dimenhydrinate—Tachycardia—Carmustine—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Dimenhydrinate—Anorexia—Carmustine—lymphatic system cancer	0.00471	0.00471	CcSEcCtD
Dimenhydrinate—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00467	0.00467	CcSEcCtD
Dimenhydrinate—Confusional state—Mitoxantrone—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Dimenhydrinate—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00462	0.00462	CcSEcCtD
Dimenhydrinate—Hypotension—Carmustine—lymphatic system cancer	0.00462	0.00462	CcSEcCtD
Dimenhydrinate—Nausea—Fludarabine—lymphatic system cancer	0.00459	0.00459	CcSEcCtD
Dimenhydrinate—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00456	0.00456	CcSEcCtD
Dimenhydrinate—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.0045	0.0045	CcSEcCtD
Dimenhydrinate—Urticaria—Bleomycin—lymphatic system cancer	0.0045	0.0045	CcSEcCtD
Dimenhydrinate—Anorexia—Vincristine—lymphatic system cancer	0.0045	0.0045	CcSEcCtD
Dimenhydrinate—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Dimenhydrinate—Insomnia—Carmustine—lymphatic system cancer	0.00447	0.00447	CcSEcCtD
Dimenhydrinate—Irritability—Methotrexate—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Dimenhydrinate—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Dimenhydrinate—Paraesthesia—Carmustine—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Dimenhydrinate—Hypotension—Vincristine—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Dimenhydrinate—Somnolence—Carmustine—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Dimenhydrinate—Anorexia—Mitoxantrone—lymphatic system cancer	0.00438	0.00438	CcSEcCtD
Dimenhydrinate—Decreased appetite—Carmustine—lymphatic system cancer	0.0043	0.0043	CcSEcCtD
Dimenhydrinate—Hypotension—Mitoxantrone—lymphatic system cancer	0.0043	0.0043	CcSEcCtD
Dimenhydrinate—Insomnia—Vincristine—lymphatic system cancer	0.00427	0.00427	CcSEcCtD
Dimenhydrinate—Paraesthesia—Vincristine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Dimenhydrinate—Constipation—Carmustine—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Dimenhydrinate—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Dimenhydrinate—Decreased appetite—Vincristine—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Dimenhydrinate—Somnolence—Mitoxantrone—lymphatic system cancer	0.00409	0.00409	CcSEcCtD
Dimenhydrinate—Feeling abnormal—Carmustine—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Dimenhydrinate—Fatigue—Vincristine—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Dimenhydrinate—Asthenia—Bleomycin—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Dimenhydrinate—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Dimenhydrinate—Constipation—Vincristine—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Dimenhydrinate—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.004	0.004	CcSEcCtD
Dimenhydrinate—Fatigue—Mitoxantrone—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Dimenhydrinate—Constipation—Mitoxantrone—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Dimenhydrinate—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Dimenhydrinate—Dysuria—Methotrexate—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Dimenhydrinate—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Dimenhydrinate—Urticaria—Mitoxantrone—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Dimenhydrinate—Vomiting—Bleomycin—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Dimenhydrinate—Drowsiness—Methotrexate—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Dimenhydrinate—Rash—Bleomycin—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Dimenhydrinate—Dermatitis—Bleomycin—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Dimenhydrinate—Asthenia—Carmustine—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Dimenhydrinate—Asthenia—Vincristine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Dimenhydrinate—Diarrhoea—Carmustine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Dimenhydrinate—Nausea—Bleomycin—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Dimenhydrinate—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Dimenhydrinate—Asthenia—Mitoxantrone—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Dimenhydrinate—Dizziness—Carmustine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Dimenhydrinate—Diarrhoea—Vincristine—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Dimenhydrinate—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Dimenhydrinate—Vomiting—Carmustine—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Dimenhydrinate—Dizziness—Vincristine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Dimenhydrinate—Rash—Carmustine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Dimenhydrinate—Dermatitis—Carmustine—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Dimenhydrinate—Headache—Carmustine—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Dimenhydrinate—Tinnitus—Methotrexate—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Dimenhydrinate—Vomiting—Vincristine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Dimenhydrinate—Rash—Vincristine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Dimenhydrinate—Dermatitis—Vincristine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Dimenhydrinate—Headache—Vincristine—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Dimenhydrinate—Nausea—Carmustine—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Dimenhydrinate—Vomiting—Mitoxantrone—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Dimenhydrinate—Rash—Mitoxantrone—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Dimenhydrinate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Dimenhydrinate—Chills—Methotrexate—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Dimenhydrinate—Headache—Mitoxantrone—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Dimenhydrinate—Nausea—Vincristine—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Dimenhydrinate—Nausea—Mitoxantrone—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Dimenhydrinate—Vision blurred—Methotrexate—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Dimenhydrinate—Vertigo—Methotrexate—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Dimenhydrinate—Convulsion—Methotrexate—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Dimenhydrinate—Confusional state—Methotrexate—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Dimenhydrinate—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Dimenhydrinate—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Dimenhydrinate—Anorexia—Methotrexate—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Dimenhydrinate—Hypotension—Methotrexate—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Dimenhydrinate—Insomnia—Methotrexate—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Dimenhydrinate—Paraesthesia—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Dimenhydrinate—Somnolence—Methotrexate—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Dimenhydrinate—Dyspepsia—Methotrexate—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Dimenhydrinate—Decreased appetite—Methotrexate—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Dimenhydrinate—Fatigue—Methotrexate—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Dimenhydrinate—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Dimenhydrinate—Urticaria—Methotrexate—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Dimenhydrinate—Asthenia—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Dimenhydrinate—Diarrhoea—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Dimenhydrinate—Dizziness—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Dimenhydrinate—Vomiting—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Dimenhydrinate—Rash—Methotrexate—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Dimenhydrinate—Dermatitis—Methotrexate—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Dimenhydrinate—Headache—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Dimenhydrinate—Nausea—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
